Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Priapism in Nigeria (PIN) Trial
PACTR202105561969346Phase 2Not yet recruiting
- Sponsor
- Vanderbilt University Medical Center
- Start
- Jul 2021
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Priapism and sickle cell disease (SCD) comparing Tadalafil + hydroxyurea with Placebo + hydroxyurea (2 arms). Primary endpoints: Recruitment rate, Trial drug adherence rate and 2 more. Planned start Jul 2021; status: not yet recruiting.
02
Drugs
tadalafilhydroxyurea
03
Conditions
Priapismsickle cell disease (SCD)
Beyond the preview
Go deeper on PACTR202105561969346.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202105561969346.